204 results on '"Nicolazzo, Chiara"'
Search Results
2. An organoid model of colorectal circulating tumor cells with stem cell features, hybrid EMT state and distinctive therapy response profile
3. Blood Extracellular Vesicles Beyond Circulating Tumour Cells: A Valuable Risk Stratification Biomarker in High-Risk Non-Muscle-Invasive Bladder Cancer Patients.
4. Circulating Cancer-Associated Macrophage-like Cells as a Blood-Based Biomarker of Response to Immune Checkpoint Inhibitors
5. A Fast and Furious Liquid Biopsy Assay to Monitor Targeted Therapy Resistance
6. Early Detection of Disease Progression in Metastatic Cancers: Could CTCs Improve RECIST Criteria?
7. About RAS Mutation Clearance in Plasma ctDNA From RAS-Mutant Colorectal Cancer Patients
8. Prognostic Role of Circulating Tumor Cell Trajectories in Metastatic Colorectal Cancer
9. Genomic landscape and survival analysis of ctDNA “neo-RAS wild-type” patients with originally RAS mutant metastatic colorectal cancer
10. Molecular Characterization of Circulating Tumor Cells to Study Cancer Immunoevasion
11. The long-term prognostic value of survivin expressing circulating tumor cells in patients with high-risk non-muscle invasive bladder cancer (NMIBC)
12. An Orthotopic Patient-Derived Xenograft (PDX) Model Allows the Analysis of Metastasis-Associated Features in Colorectal Cancer
13. Response to immunotherapy in KRAS G12C mutated NSCLC: a single-centre retrospective observational study
14. Additional file 1 of An organoid model of colorectal circulating tumor cells with stem cell features, hybrid EMT state and distinctive therapy response profile
15. RAS Mutation Conversion in Bevacizumab-Treated Metastatic Colorectal Cancer Patients: A Liquid Biopsy Based Study
16. In vitro cultures of circulating tumor cells: a potential tool to unravel drug sensitivity
17. Sequential Isolation and Characterization of Single CTCs and Large CTC Clusters in Metastatic Colorectal Cancer Patients
18. Comparison of Two Blood-Based Genotyping Tests to Investigate the KRAS G12C Mutation in Patients with Non-Small-Cell Lung Cancer at Failure of First-Line Treatments
19. True conversions from RAS mutant to RAS wild-type in circulating tumor DNA from metastatic colorectal cancer patients as assessed by methylation and mutational signature
20. Epithelial-mesenchymal transition and stemness features in circulating tumor cells from breast cancer patients
21. Circulating tumor cells detection has independent prognostic impact in high-risk non-muscle invasive bladder cancer
22. Liquid Biopsy for Predicting Bacillus Calmette-Guérin Unresponsiveness in Non–muscle-invasive Bladder Cancer
23. Circulating Methylated DNA to Monitor the Dynamics of RAS Mutation Clearance in Plasma from Metastatic Colorectal Cancer Patients
24. Circulating tumour cells lacking cytokeratin in breast cancer: the importance of being mesenchymal
25. Baseline CD44v6-positive circulating tumor cells to predict first-line treatment failure in patients with metastatic colorectal cancer
26. Molecular Biomarkers according to Primary Tumor Location in Colorectal Cancer: Current Standard and New Insights
27. Detection of circulating tumor cells in patients with laryngeal cancer using ScreenCell: Comparative pre- and post-operative analysis and association with prognosis
28. Prognostic significance of survivin-expressing circulating tumour cells in T1G3 bladder cancer
29. Molecular markers in circulating tumour cells from metastatic colorectal cancer patients
30. Why the Therapeutic Impact of RAS Mutation Clearance in Plasma ctDNA Deserves to Be Further Explored in Metastatic Colorectal Cancer
31. EpCAMlow Circulating Tumor Cells: Gold in the Waste
32. Circulating tumor cells: from fiction to reality
33. Circulating Tumor Cells in Right- and Left-Sided Colorectal Cancer
34. Circulating Tumor Cells Identify Patients with Super-High-Risk Non-Muscle-Invasive Bladder Cancer: Updated Outcome Analysis of a Prospective Single-Center Trial
35. Improving the Nuclear-Localized Androgen Receptor Splice Variant 7 Test
36. Transient Disappearance of RAS Mutant Clones in Plasma: A Counterintuitive Clinical Use of EGFR Inhibitors in RAS Mutant Metastatic Colorectal Cancer
37. Molecular Biomarkers according to Primary Tumor Location in Colorectal Cancer: Current Standard and New Insights.
38. Coexistence of three EGFR mutations in an NSCLC patient: A brief report
39. Liquid Biopsy in Rare Cancers: Lessons from Hemangiopericytoma
40. Razionale per la biopsia liquida nel carcinoma del colon-retto: focus sulle cellule tumorali circolanti
41. EpCAM-Expressing Circulating Tumor Cells in Colorectal Cancer
42. Letter to the Editor: “Circulating Cell-Free DNA and Circulating Tumor Cells as Prognostic and Predictive Biomarkers in Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Chemotherapy”
43. PD-L1 and epithelial-mesenchymal transition in circulating tumor cells from non-small cell lung cancer patients: A molecular shield to evade immune system?
44. Significance of Circulating Tumor Cells in Soft Tissue Sarcoma
45. EpCAMlow Circulating Tumor Cells: Gold in the Waste.
46. Monitoring PD-L1 positive circulating tumor cells in non-small cell lung cancer patients treated with the PD-1 inhibitor Nivolumab
47. New thiadiazoline and thiadiazole analogues of K858: antiproliferative activity in a model of prostate carcinoma
48. SURVIVIN EXPRESSING CIRCULATING TUMOR CELLS IN NONMUSCHE INVASIVE BLADDER CANCER: A CELLECTION™ DYNABEADS ANALYSIS
49. CIRCULATING TUMOR CELLS AND THEIR PROGNOSTICSIGNIFICANCE IN NON MUSCLE INVASIVE BLADDER CANCER:A CELLSEARCH ANALYSIS
50. HIGH-RISK NMIBC (NON-MUSCLE INVASIVE BLADDERCANCER): PROGNOSTIC VALUE OF CIRCULATINGTUMOR CELLS
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.